Sagimet Biosciences Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Sagimet is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors. It has no approved products and has not generated product-sale revenue; revenue to date has come from licensing arrangements.
Financial performance and liquidity
| Metric | Q3 2023 | Nine months 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | $2.0 million | $2.0 million | None |
| Research and development expense | $5.0 million | $14.1 million | $6.8 million; $19.1 million |
| General and administrative expense | $4.5 million | $9.2 million | $0.8 million; $4.6 million |
| Net loss | $6.4 million | $19.7 million | $7.5 million; $23.3 million |
| Operating cash used | Not separately stated | $16.7 million | $17.0 million |
Q3 operating expenses rose 23% year over year, but the net loss narrowed by 15%, supported by the license revenue and higher interest income. For the nine-month period, operating expenses declined 2% and net loss narrowed 15%. R&D expense fell as FASCINATE-2 trial costs declined while patients progressed through the trial; G&A increased, including public-company, IPO, executive hiring and stock-compensation costs. Operating margins are not meaningful for this development-stage company.
At September 30, cash and cash equivalents were $101.8 million, with no short-term investments and $5.0 million of total liabilities. The filing reports no outstanding debt; operating lease liabilities were $0.1 million. The IPO generated approximately $86.2 million in net proceeds. Investing activities provided $32.2 million, primarily from sales of marketable securities; financing activities provided $86.2 million. Management said available cash was expected to fund operating expenses and capital requirements for at least 12 months from the November 13, 2023 issuance date. The company expects continued losses and negative operating cash flows and anticipates needing additional capital.
Material changes and unusual items
- The July 2023 IPO sold 5,312,500 Series A shares at $16 per share, including additional shares sold through partial exercise of the underwriters’ option; gross proceeds were $96.4 million and net proceeds approximately $86.2 million. Preferred stock converted into 15.1 million Series A and 1.5 million Series B shares. Series B shares are generally non-voting and convertible into Series A, subject to ownership limits.
- A $2.0 million development milestone from Ascletis was recognized as license revenue after the company concluded the risk of reversal had passed. The company received $1.7 million after applicable taxes in August 2023.
- Q3 interest income and other increased to $1.1 million from $0.2 million, mainly reflecting interest earned on IPO proceeds.
- Q3 stock-based compensation was $1.9 million, versus $0.4 million a year earlier; nine-month expense was $3.7 million versus $1.2 million.
Outlook, commentary and risks
Management expected topline liver-biopsy results from the FASCINATE-2 Phase 2b trial in NASH in the first quarter of 2024. The filing cites earlier interim results presented in November 2022, including an approximately 34% reduction in liver fat and a 67% responder rate at 26 weeks; these are prior trial findings, not Q3 results. The company also evaluates FASN inhibition in other potential disease areas, including acne and certain cancers.
Funding and development remain dependent on clinical progress, regulatory outcomes, third-party research and manufacturing providers, and access to additional capital. Delays in enrollment, adverse effects, competition, supply or contractor problems, and financing-market conditions could affect costs and timelines. COVID-related site closures had previously caused modest FASCINATE-2 enrollment delays. The company reported no material change in risk factors from its prior quarterly filing, no material legal proceedings, and no subsequent events requiring disclosure. Disclosure controls were assessed as effective at September 30, 2023.
Investor facts to verify
- Whether FASCINATE-2 topline results arrived on the stated schedule and how the full biopsy data compare with earlier interim findings.
- Cash burn, cash runway and financing needs as clinical-development spending and public-company costs evolve.
- The terms, timing and collectability of remaining Ascletis/Gannex milestones and potential royalties; the agreement permits Ascletis to terminate for convenience on 90 days’ notice.
- Potential dilution from outstanding options and future equity issuance; 3.77 million options were outstanding at September 30, 2023.
- Clinical, regulatory, manufacturing and third-party execution risks, including whether trial enrollment or other operational delays recur.